BNP Paribas Financial Markets
CPIX icon

BNP Paribas Financial Markets’s Cumberland Pharmaceuticals CPIX Stock Holding History

BNP Paribas Financial Markets’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-66
Closed -$297 – 4117
2014
Q2 		$297 Hold
66
– – ﹤0.01% 3663
2014
Q1 		$294 Hold
66
– – ﹤0.01% 3149
2013
Q4 		$337 Buy
+66
New +$322 ﹤0.01% 3984

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GHA
GW Henssler & Associates Kennesaw, Georgia $2.12B AUM 20.77% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BNP Paribas Financial Markets's CPIX Position: Q3 2014 in Review

BNP Paribas Financial Markets sold out of Cumberland Pharmaceuticals (CPIX) in Q3 2014, closing a stake of 66 shares — an estimated $297 sold.

BNP Paribas Financial Markets first reported a position in CPIX in Q4 2013 and held it in 3 quarters. The position peaked at $337 in Q4 2013. 45 funds tracked by Wall St. Rank hold CPIX as of Q3 2014.

  • BNP Paribas Financial Markets reported no remaining Cumberland Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 66 Cumberland Pharmaceuticals shares in Q3 2014, an estimated $297.
  • BNP Paribas Financial Markets first reported a position in Cumberland Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • BNP Paribas Financial Markets's Cumberland Pharmaceuticals position peaked at $337 in Q4 2013.
  • 45 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q3 2014.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2014, filed 12 Nov 2014.